ASIA-PACIFIC ALZHEIMER’S DISEASE THERAPEUTICS AND DIAGNOSTIC MARKET 2019-2027

Lifesciences | Diagnostic & Biotechnology

ASIA-PACIFIC ALZHEIMER’S DISEASE THERAPEUTICS AND DIAGNOSTIC MARKET 2019-2027

Market By Therapeutics & Diagnostics And Geography | Forecast 2019-2027

Request Free Sample

Request Custom Report

Request Custom Report

Enquire before buying

Enquire Before Buying

With the largest share of the world’s population, the Asia-Pacific Alzheimer’s disease therapeutics and diagnostics market is expected to rise at a CAGR of 8.79% during the forecast period of 2019-2027.

The countries studied in the Asia-Pacific Alzheimer’s disease therapeutics and diagnostics market include:

•  China

•  India

•  Japan

•  South Korea

•  ASEAN countries

•  Australia & New Zealand

•  Rest of Asia-Pacific

Alzheimer’s is one of the most prevalent neurodegenerative disorders. It causes problems like loss of memory, changes in behavior and challenges in thinking. In the initial stages, the memory loss would be mild, but it gets worse as the sickness prolongs, affecting the victim’s daily activities and reducing the effectiveness in responding to stimuli. One of the prime challenges faced by the market is the limited availability of therapeutic alternatives and procedures that are incapable of providing optimal diagnostics in stipulated time. The Asia-Pacific is the most densely populated region, indicating the vast procurement and manufacturing infrastructure required to tackle such a crowd. Hence, overcoming these challenges will provide a huge potential for the market and the companies equipped in the industry.

With the ever-growing number of people reporting neurodegenerative disease symptoms, the demand for Alzheimer’s diagnostic tests and new drug development at affordable costs has also risen in countries like China, India, Japan and rest of Asia-Pacific. As a result, governments in these countries have taken multiple initiatives and investment plans for the development of personalized drugs and digitizing the medical field to manage real-time health check-ups of patients to provide medical aid at the early sightings of signs & symptoms and ultimately control the rising cases of neurodegenerative diseases.

Sun Pharmaceuticals Industries Ltd. is a generic pharmaceutical company that manufactures and sells pharmaceutical products & formulation and APIs in India and other countries. Established in 1961, the company has over 50 years of experience in developing the pharma products. Sun Pharma has received approval from the FDA for manufacturing generic drugs for Alzheimer; it thus plans to expand its business in the overseas market owing to the huge demand for the cure of Alzheimer. With over 40 manufacturing facilities and 30,000 employees across the globe, Sun Pharmaceuticals is headquartered in Mumbai, India.


The top key players in the Alzheimer’s disease therapeutics and diagnostics market include AbbVie, Amarantus BioScience Holdings Inc., AXON Neuroscience SE, Baxter, Biogen, Cognoptix, DiaGenic ASA, Roche, GE Healthcare, Merck, Johnson & Johnson, Piramal Enterprises Ltd., Siemens Healthineers AG, and Sun Pharmaceutical Industries Ltd.

Related Reports

ASIA PACIFIC AESTHETIC LASER MARKET 2019-2027
Lifesciences

ASIA PACIFIC AESTHETIC LASER MARKET 2019-2027

Market By Type, Application, E ..

VIEW REPORT
ASIA PACIFIC BIOCHIPS MARKET 2019-2027
Lifesciences

ASIA PACIFIC BIOCHIPS MARKET 2019-2027

Market By Type, Substrate Mate ..

VIEW REPORT
ASIA PACIFIC BIOPSY DEVICE MARKET 2019-2027
Lifesciences

ASIA PACIFIC BIOPSY DEVICE MARKET 2019-2027

Market By Device Type, Therape ..

VIEW REPORT
ASIA PACIFIC DNA VACCINES MARKET 2019-2027
Lifesciences

ASIA PACIFIC DNA VACCINES MARKET 2019-2027

Market By Type, Application, T ..

VIEW REPORT
ASIA-PACIFIC 3D CELL CULTURE MARKET 2019-2027
Lifesciences

ASIA-PACIFIC 3D CELL CULTURE MARKET 2019-2027

Market By Technology, Applicat ..

VIEW REPORT
ASIA-PACIFIC AIRWAY CLEARANCE SYSTEM MARKET 2019-2028
Lifesciences

ASIA-PACIFIC AIRWAY CLEARANCE SYSTEM MARKET 2019-2028

Market By Application, Type, E ..

VIEW REPORT

Table of Content

1.    ASIA-PACIFIC ALZHEIMER’S DISEASE THERAPEUTICS AND DIAGNOSTIC MARKET - SUMMARY

2.    INDUSTRY OUTLOOK

2.1. MARKET DEFINITION

2.2. PORTER’S FIVE FORCE MODEL

2.2.1. THREAT OF NEW ENTRANTS

2.2.2. THREATS OF SUBSTITUTE PRODUCT

2.2.3. BARGAINING POWER OF BUYER

2.2.4. BARGAINING POWER OF SUPPLIER

2.2.5. INTENSITY OF COMPETITIVE RIVALRY

2.3. VENDOR SCORECARD

2.4. ETYMOLOGY

2.5. PARENT MARKET OUTLOOK

2.6. STRATEGIC BUYING CRITERIA OUTLOOK

2.7. KEY FINDINGS

2.8. INDUSTRY STRUCTURE

2.8.1. RESEARCH AND DEVELOPMENT

2.8.2. MANUFACTURING

2.8.3. RAW MATERIALS

2.8.4. END USER

2.8.5. WHOLESALERS

2.9. REGULATORY FRAMEWORK

2.10. ALZHEIMER'S DISEASE ETIOLOGY

2.11. PHASES AND STERNNESS OF ALZHEIMER’S DISEASE

2.12. MARKET DRIVERS

2.12.1. GROWTH OF ALZHEIMER’S DISEASE

2.12.2. GROWING GERIATRIC POPULATION

2.12.3. SUBSTANTIAL INVESTMENTS BY GOVERNMENT IN RESEARCH

2.13. MARKET RESTRAINTS

2.13.1. STRINGENT GOVERNMENT REGULATIONS

2.13.2. THE TREATMENT OF ALZHEIMER’S DISEASE COSTS VERY HIGH

2.14. MARKET OPPORTUNITIES

2.14.1. IN-VITRO DIAGNOSTIC TECHNIQUES ARE A BOON TO THE MARKET

2.14.2. R&D INVESTMENT IN THE PERSONALIZED MEDICINES IS INCREASING

2.15. MARKET CHALLENGES

2.15.1. AWARENESS IS LESS CONCERNING NEW THERAPIES IN THE ALZHEIMER’S DISEASE

2.15.2. VERY FEW SKILLED PROFESSIONALS PERTAINING TO THE TREATMENT OF ALZHEIMER’S DISEASE

3.    ALZHEIMER’S DISEASE THERAPEUTICS AND DIAGNOSTICS MARKET OUTLOOK - BY THERAPEUTICS AND DIAGNOSTICS

3.1. THERAPEUTICS

3.1.1. THERAPEUTICS BY DRUGS

3.1.1.1. MARKETED DRUGS

3.1.1.2. PIPELINE DRUGS

3.1.2. THERAPEUTICS BY DISEASE STAGE

3.1.2.1. LATE STAGE: SEVERE AD

3.1.2.2. EARLY/MIDDLE STAGE: MILD TO MODERATE AD

3.1.3. PRODROMAL STAGE

3.1.4. THERAPEUTICS BY GENERIC AND BRANDED

3.1.4.1. BRANDED

3.1.4.2. GENERIC

3.2. DIAGNOSTIC TYPE

3.2.1. LUMBAR PUNCTURE TEST

3.2.2. POSITRON EMISSION TOMOGRAPHY

3.2.3. ELECTROENCEPHALOGRAPHY

3.2.4. MAGNETIC RESONANCE IMAGING

3.2.5. COMPUTED TOMOGRAPHY

3.2.6. OTHER DIAGNOSTICS

4.    ALZHEIMER’S DISEASE THERAPEUTICS AND DIAGNOSTICS MARKET – ASIA-PACIFIC

4.1. MARKET BY THERAPEUTICS AND DIAGNOSTICS

4.2. COUNTRY ANALYSIS

4.2.1. CHINA

4.2.2. INDIA

4.2.3. JAPAN

4.2.4. AUSTRALIA AND NEW ZEALAND

4.2.5. SOUTH KOREA

4.2.6. ASEAN COUNTRIES

4.2.7. REST OF ASIA-PACIFIC

5.    COMPANY PROFILES

5.1. ABBVIE

5.2. AMARANTUS BIOSCIENCE HOLDINGS, INC.

5.3. AXON NEUROSCIENCE SE

5.4. BAXTER

5.5. BIOGEN

5.6. COGNOPTIX

5.7. DIAGENIC ASA

5.8. ROCHE

5.9. GE HEALTHCARE

5.10. MERCK

5.11. JOHNSON & JOHNSON

5.12. PIRAMAL ENTERPRISES LTD.

5.13. SIEMENS HEALTHINEERS AG

5.14. SUN PHARMACEUTICAL INDUSTRIES LTD.

6.    RESEARCH METHODOLOGY & SCOPE

6.1. RESEARCH SCOPE & DELIVERABLES

6.1.1. OBJECTIVES OF STUDY

6.1.2. SCOPE OF STUDY

6.2. SOURCES OF DATA

6.2.1. PRIMARY DATA SOURCES

6.2.2. SECONDARY DATA SOURCES

6.3. RESEARCH METHODOLOGY

6.3.1. EVALUATION OF PROPOSED MARKET

6.3.2. IDENTIFICATION OF DATA SOURCES

6.3.3. ASSESSMENT OF MARKET DETERMINANTS

6.3.4. DATA COLLECTION

6.3.5. DATA VALIDATION & ANALYSIS

List of table

TABLE 1        ASIA-PACIFIC ALZHEIMER’S DISEASE THERAPEUTICS AND DIAGNOSTICS MARKET 2019-2027 ($ MILLION)

TABLE 2        ASIA-PACIFIC ALZHEIMER’S DISEASE THERAPEUTICS AND DIAGNOSTICS MARKET IN THERAPEUTICS BY DRUGS 2019-2027 ($ MILLION)

TABLE 3        ASIA-PACIFIC ALZHEIMER’S DISEASE THERAPEUTICS AND DIAGNOSTICS MARKET IN DISEASE STAGE BY DRUGS 2019-2027 ($ MILLION)

TABLE 4        ASIA-PACIFIC ALZHEIMER’S DISEASE THERAPEUTICS AND DIAGNOSTICS MARKET IN THERAPEUTICS BY GENERIC AND BRANDED 2019-2027 ($ MILLION)

TABLE 5        ASIA-PACIFIC ALZHEIMER’S DISEASE DIAGNOSTICS MARKET BY DIAGNOSTIC TYPE 2019-2027 ($ MILLION)

TABLE 6        ASIA-PACIFIC ALZHEIMER’S DISEASE THERAPEUTICS AND DIAGNOSTICS MARKET BY THERAPEUTICS AND DIAGNOSTICS 2019-2027 ($ MILLION)

TABLE 7        ASIA-PACIFIC ALZHEIMER’S DISEASE THERAPEUTICS AND DIAGNOSTICS MARKET BY COUNTRY 2019-2027 ($ MILLION)         

List of Figures

FIGURE 1      ASIA-PACIFIC ALZHEIMER’S DISEASE THERAPEUTICS AND DIAGNOSTICS MARKET 2019-2027 ($ MILLION)

FIGURE 2      ASIA-PACIFIC ALZHEIMER’S DISEASE THERAPEUTICS AND DIAGNOSTICS MARKET IN THERAPEUTICS 2019-2027 ($ MILLION)

FIGURE 3      ASIA-PACIFIC ALZHEIMER’S DISEASE THERAPEUTICS MARKET IN MARKETED DRUGS 2019-2027 ($ MILLION)

FIGURE 4      ASIA-PACIFIC ALZHEIMER’S DISEASE THERAPEUTICS MARKET IN PIPELINE DRUGS 2019-2027 ($ MILLION)

FIGURE 5      ASIA-PACIFIC ALZHEIMER’S DISEASE THERAPEUTICS MARKET IN LATE STAGE: SEVERE AD 2019-2027 ($ MILLION)

FIGURE 6      ASIA-PACIFIC ALZHEIMER’S DISEASE THERAPEUTICS MARKET IN EARLY/MIDDLE STAGE: MILD TO MODERATE AD 2019-2027 ($ MILLION)

FIGURE 7      ASIA-PACIFIC ALZHEIMER’S DISEASE THERAPEUTICS MARKET IN PRODROMAL STAGE 2019-2027 ($ MILLION)

FIGURE 8      ASIA-PACIFIC ALZHEIMER’S DISEASE THERAPEUTICS MARKET IN BRANDED 2019-2027 ($ MILLION)

FIGURE 9      ASIA-PACIFIC ALZHEIMER’S DISEASE THERAPEUTICS MARKET IN GENERIC 2019-2027 ($ MILLION)

FIGURE 10   ASIA-PACIFIC ALZHEIMER’S DISEASE THERAPEUTICS AND DIAGNOSTICS MARKET IN DIAGNOSTICS 2019-2027 ($ MILLION)

FIGURE 11   ASIA-PACIFIC ALZHEIMER’S DISEASE DIAGNOSTICS MARKET IN LUMBAR PUNCTURE TEST 2019-2027 ($ MILLION)

FIGURE 12   ASIA-PACIFIC ALZHEIMER’S DISEASE DIAGNOSTICS MARKET IN POSITRON EMISSION TOMOGRAPHY 2019-2027 ($ MILLION)

FIGURE 13   ASIA-PACIFIC ALZHEIMER’S DISEASE DIAGNOSTICS MARKET IN ELECTROENCEPHALOGRAPHY 2019-2027 ($ MILLION)

FIGURE 14   ASIA-PACIFIC ALZHEIMER’S DISEASE DIAGNOSTICS MARKET IN MAGNETIC RESONANCE IMAGING 2019-2027 ($ MILLION)

FIGURE 15   ASIA-PACIFIC ALZHEIMER’S DISEASE DIAGNOSTICS MARKET IN COMPUTED TOMOGRAPHY 2019-2027 ($ MILLION)

FIGURE 16   ASIA-PACIFIC ALZHEIMER’S DISEASE DIAGNOSTICS MARKET IN OTHER DIAGNOSTICS 2019-2027 ($ MILLION)

FIGURE 17   INDIA ALZHEIMER’S DISEASE THERAPEUTICS AND DIAGNOSTICS MARKET 2019-2027 ($ MILLION)

FIGURE 18   JAPAN ALZHEIMER’S DISEASE THERAPEUTICS AND DIAGNOSTICS MARKET 2019-2027 ($ MILLION)

FIGURE 19   AUSTRALIA AND NEW ZEALAND ALZHEIMER’S DISEASE THERAPEUTICS AND DIAGNOSTICS MARKET 2019-2027 ($ MILLION)

FIGURE 20   SOUTH KOREA ALZHEIMER’S DISEASE THERAPEUTICS AND DIAGNOSTICS MARKET 2019-2027 ($ MILLION)

FIGURE 21   ASEAN COUNTRIES ALZHEIMER’S DISEASE THERAPEUTICS AND DIAGNOSTICS MARKET 2019-2027 ($ MILLION)

FIGURE 22   REST OF ASIA-PACIFIC ALZHEIMER’S DISEASE THERAPEUTICS AND DIAGNOSTICS MARKET 2019-2027 ($ MILLION)

Purchase Options

  • Licence Type
  • Price
  • User/Sharing
  • Printing
  • Delivery Formats
  • Free customization (Pre-sale)
  • Analyst hour support (Post Sale)
  • Customized notification for newly published report
  • Free report on update (within 180 days)

Single User PDF

$1,500.00

  • User/Sharing
  • Restricted to one authorized user
  • Printing
  • Not printable
  • Delivery Formats
  • Pdf
  • Free customization (Pre-sale)
  • 10% Free customization
  • Analyst hour support (Post Sale)
  • 3 hours
  • Customized notification (newly published)
  • Free report on update (within 180 days)

Enterprise Online/PDF

$2,200.00

  • User/Sharing
  • Unlimited
  • Printing
  • Unlimited
  • Delivery Formats
  • Pdf and market estimation excel
  • Free customization (Pre-sale)
  • 20% Free customization
  • Analyst hour support (Post Sale)
  • 8 hour
  • Customized notification (newly published)
  • Free report on update (within 180 days)

Request free Sample

SUBMIT REQUEST
Request Custom Report

Request Custom Report

Enquire before buying

Enquire Before Buying

;